Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center have begun construction on an estimated $1.68 billion cancer hospital in Boston.
The work begins with the deconstruction of the former Joslin Diabetes Center building at 1 Joslin Place in Boston’s Longwood Medical Area, according to an April 7 news release.
Joslin Diabetes Center has relocated its clinics, clinical research center and research laboratories to sites on Beth Israel Deaconess Medical Center’s East Campus and the Center for Life Science to enable the deconstruction.
The 300-bed hospital, announced in September 2023 and approved by the Boston Planning Department in October 2024, will span 450,000 square feet across 10 inpatient floors and is expected to open in 2031.
The project comes as Dana-Farber prepares to end its longtime partnership with Boston-based Brigham and Women’s Hospital.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
